HC Wainwright Reiterates “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 148.45% from the stock’s previous close.

A number of other research firms have also weighed in on ATXS. JMP Securities began coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective on the stock. Oppenheimer boosted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.67.

Astria Therapeutics Trading Up 2.1 %

Shares of ATXS stock opened at $6.44 on Thursday. The company has a market capitalization of $363.43 million, a P/E ratio of -3.08 and a beta of 0.67. The business’s 50 day moving average is $7.70 and its two-hundred day moving average is $9.89. Astria Therapeutics has a twelve month low of $6.20 and a twelve month high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Large investors have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS acquired a new position in Astria Therapeutics during the fourth quarter worth about $41,000. Tower Research Capital LLC TRC boosted its stake in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Astria Therapeutics in the 4th quarter worth approximately $50,000. Virtus ETF Advisers LLC purchased a new position in Astria Therapeutics in the 4th quarter valued at approximately $65,000. Finally, Quest Partners LLC raised its holdings in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,798 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.